Insight Molecular Diagnostics Q2 FY26 net loss widens to $11.26 million; revenue falls to $239,000

Reuters2026/08/10 20:18

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold. Trade now!

A welcome pack worth 6200 USDT for new users! Sign up now!

Insight Molecular Diagnostics posted Q2 2026 revenue of USD 239,000, down 53.86% from USD 518,000 a year earlier.
Net loss widened to USD 11.3 million, or USD 0.31 per share, from USD 9.74 million, or USD 0.30 per share.
Non-GAAP adjusted net loss widened to USD 8.32 million, or USD 0.23 per share, from USD 6.43 million, or USD 0.20 per share.
Cash, cash equivalents, and restricted cash totaled USD 18.7 million at quarter-end; operating cash outflow was USD 9.27 million.
FDA completed the current phase of substantive review of GraftAssureDx in late July, requesting additional information as review advances toward expected marketing authorization.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Insight Molecular Diagnostics Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202608101605PRIMZONEFULLFEED9806958) on August 10, 2026, and is solely responsible for the information contained therein.

Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.

Understand the market, then trade.

Bitget offers one-stop trading for cryptocurrencies, stocks, and gold.

Trade now！

Insight Molecular Diagnostics Q2 FY26 net loss widens to $11.26 million; revenue falls to $239,000

You may also like

Crypto prices